Body mass index in dementia

García-Ptacek, Sara; Irving, Gerd Faxén; Čermáková, Pavla; Eriksdotter, Maria; Religa, Dorota

doi:10.1038/ejcn.2014.199

Cited by 80 publications

(76 citation statements)

References 85 publications

(105 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For instance, previous studies have reported the association between body mass index (BMI) and the incidence of dementia [54, 55], and Koreans generally tend to have lower BMI than westerners. Based on the national health and nutrition examination surveys conducted in Korea and in the United States, the average BMI among the elderly population was 23.8 kg/m 2 (SD: 3.2) in Korea [56], and 28.3 kg/m 2 (SD: 7.1) in the United States [57].…”

Section: Discussionmentioning

confidence: 99%

The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea

Park

Song

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

Dementia is a major concern among growing chronic diseases in the aging society and its association with polypharmacy has not been adequately assessed. The objective of this study was to determine the association between polypharmacy and dementia through multiple statistical approaches. We conducted a nested case-control study for newly diagnosed dementia cases using the South Korean National Health Insurance Service sample cohort database (2002–2013, n = 1,025,340). Interactions between polypharmacy (an average use of ≥5 prescription drugs daily) and comorbidities or potentially inappropriate medications (PIMs) were tested. The odds ratios (ORs) for dementia were analyzed according to the presence of comorbidities, PIM uses, the average number of prescribed daily drugs, and significant interactions with polypharmacy using univariate and multiple logistic regression analyses. A higher prevalence of comorbidities, history of PIM use, higher PIM exposure, and higher proportion of polypharmacy were noted among cases than in controls. In the univariate analysis, the OR for dementia increased significantly with the increase in the number of prescribed drugs [1–<5 drugs: 1.72, 95% confidence interval (CI): 1.56–1.88; 5–<10 drugs: 2.64, 95% CI: 2.32–3.05; ≥10 drugs: 3.35, 95% CI: 2.38–4.71; <1 drug used as reference]. Polypharmacy was correlated with comorbidities and PIM use, and significant interactions were observed between polypharmacy and anticholinergics; H2-receptor antagonists; and comorbidities such as hypertension, peripheral or cerebrovascular disease, congestive heart failure, hemiplegia, diabetes, depression, all other mental disorders, chronic obstructive pulmonary disease, peptic ulcer disease, and chronic liver disease (p<0.001). In the multiple regression analysis, most cases exhibited increasing ORs for dementia with increasing polypharmacy levels. Moreover, the increase in OR was more evident in the absence of drugs or comorbidities that showed significant interactions with polypharmacy than in their presence. Polypharmacy increases the risk of PIM administration, and as some PIMs may have cognition-impairing effects, prolonged polypharmacy may result in dementia. Therefore, efforts are needed to limit or decrease the prescription of medications that have been associated with risk of dementia in the elderly.

show abstract

Section: Discussionmentioning

confidence: 99%

The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea

Park

Song

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Of particular note is the finding that rats fed a Western diet exhibited cognitive impairments even before developing substantial excess body weight gain (108). Less direct evidence comes from the human studies that show an association between obesity and decreased brain volume (109,110) and the association between obesity and later life cognitive decline and dementias (111).…”

Section: The Control Of Hedonic Food Intake: Cognitive Controlmentioning

confidence: 99%

Obesity and the Neurocognitive Basis of Food Reward and the Control of Intake

Ziauddeen

Alonso‐Alonso

Hill

et al. 2015

Advances in Nutrition

119

View full text Add to dashboard Cite

With the rising prevalence of obesity, hedonic eating has become an important theme in obesity research. Hedonic eating is thought to be that driven by the reward of food consumption and not metabolic need, and this has focused attention on the brain reward system and how its dysregulation may cause overeating and obesity. Here, we begin by examining the brain reward system and the evidence for its dysregulation in human obesity. We then consider the issue of how individuals are able to control their hedonic eating in the present obesogenic environment and compare 2 contrasting perspectives on the control of hedonic eating, specifically, enhanced control of intake via higher cognitive control and loss of control over intake as captured by the food addiction model. We conclude by considering what these perspectives offer in terms of directions for future research and for potential interventions to improve control over food intake at the population and the individual levels.

show abstract

“…According to previous studies, the association between BMI and risk for future development of AD seems to depend on the time point of BMI assessment. While higher BMI in midlife has been shown to be a risk factor for future development of AD, higher BMI in late-life is associated with a reduced AD risk 1–3 . In contrast, low BMI and accelerated weight loss in later life have been associated with increased risk of AD 4–8 .…”

Section: Introductionmentioning

confidence: 99%

Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer’s disease

Müller

Preische

Sohrabi

et al. 2017

Sci Rep

View full text Add to dashboard Cite

The relationship between body-mass index (BMI) and Alzheimer´s disease (AD) has been extensively investigated. However, BMI alterations in preclinical individuals with autosomal dominant AD (ADAD) have not yet been investigated. We analyzed cross-sectional data from 230 asymptomatic members of families with ADAD participating in the Dominantly Inherited Alzheimer Network (DIAN) study including 120 preclinical mutation carriers (MCs) and 110 asymptomatic non-carriers (NCs). Differences in BMI and their relation with cerebral amyloid load and episodic memory as a function of estimated years to symptom onset (EYO) were analyzed. Preclinical MCs showed significantly lower BMIs compared to NCs, starting 11.2 years before expected symptom onset. However, the BMI curves begun to diverge already at 17.8 years before expected symptom onset. Lower BMI in preclinical MCs was significantly associated with less years before estimated symptom onset, higher global Aβ brain burden, and with lower delayed total recall scores in the logical memory test. The study provides cross-sectional evidence that weight loss starts one to two decades before expected symptom onset of ADAD. Our findings point toward a link between the pathophysiology of ADAD and disturbance of weight control mechanisms. Longitudinal follow-up studies are warranted to investigate BMI changes over time.

show abstract

Body mass index in dementia

Cited by 80 publications

References 85 publications

The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea

The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea

Obesity and the Neurocognitive Basis of Food Reward and the Control of Intake

Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer’s disease

Contact Info

Product

Resources

About